8-K: Tempest Therapeutics Q2 2026 Update: New Collaboration, Promising Data

Tempest Therapeutics reported Q2 2026 financial results, highlighting a new development collaboration for TPST-4003, positive interim data for TPST-2003, and strategic board appointments.

Summary

• Tempest Therapeutics announced its financial results for the second quarter ended June 30, 2026.
• The company executed a development collaboration with Senlang Biotechnology to advance TPST-4003, with first patient dosing expected in Q4 2026 and initial data in H1 2027.
• Positive interim results were reported for TPST-2003 across two trials (REDEEM-1 and POEMS-1), showing a 100% complete response rate in CAR-T-naive patients and a favorable safety profile.
• Tempest appointed two new independent directors, Drake Richey and John Yee, MD, MPH, to its Board of Directors.
• The company ended the quarter with $0.8 million in cash and cash equivalents, a decrease from $7.7 million at the end of 2025.
• Net loss for Q2 2026 was $5.2 million, or $0.34 per share, an improvement from a net loss of $7.9 million, or $2.07 per share, in Q2 2025.
• Research and development expenses decreased to $1.8 million in Q2 2026 from $3.9 million in Q2 2025.
• General and administrative expenses decreased to $3.4 million in Q2 2026 from $4.1 million in Q2 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with significant strategic advancements and promising early clinical data, balanced by a continued need for capital and a decrease in cash reserves.

Positives

• Executed a development collaboration with Senlang Biotechnology for TPST-4003, targeting Q4 2026 for first patient dosing.
• Unveiled a pipeline of next-generation in vivo CAR-T product candidates, including TPST-4003.
• Reported 100% complete response rate in CAR-T-naive efficacy evaluable patients for TPST-2003 across REDEEM-1 and POEMS-1 trials.
• TPST-2003 shows a favorable safety profile with no Grade 3 CRS or ICANS in the REDEEM-1 trial.
• TPST-2003 achieved a median progression-free survival of 23.1 months in a prior investigator-initiated trial.
• Selected Cincinnati Childrens AGCTC as the lead manufacturing partner for TPST-2003, with lentiviral vector delivery completed.
• Appointed two experienced independent directors, Drake Richey and John Yee, MD, MPH, to the Board.
• Announced the appointment of Andrew Fang, Ph.D., as Head of Business Development.

Negatives

• Cash and cash equivalents decreased significantly to $0.8 million as of June 30, 2026, from $7.7 million as of December 31, 2025.
• Total assets decreased from $16.9 million to $9.6 million.
• Total liabilities increased from $10.3 million to $10.7 million.
• Stockholders' equity (deficit) turned negative, from $6.7 million to a deficit of $1.1 million.
• Acquired in-process research and development expenses of $22.1 million for the six months ended June 30, 2026, impacting the net loss.
• Net loss for the six months ended June 30, 2026, was $32.9 million, a substantial increase from $18.7 million in the prior year period.

Risks

• Tempest Therapeutics' need for additional capital to fund its planned programs and operations and to continue to operate as a going concern.
• Unexpected safety or efficacy data observed during preclinical or clinical trials.
• The possibility that results from prior clinical trials and preclinical studies may not necessarily be predictive of future results.
• Clinical trial site activation or enrollment rates that are lower than expected.
• Loss of key personnel.
• Changes in the regulatory environment.
• Risks relating to volatility and uncertainty in the capital markets for biotechnology companies.
• Unexpected litigation or other disputes.

Future Outlook

The company anticipates first patient dosing for TPST-4003 in the fourth quarter of 2026 and expects initial clinical data in the first half of 2027. The company also plans to initiate the first potentially registrational study for TPST-2003 later in 2026. Forward-looking statements indicate ongoing need for capital and potential risks related to clinical trials, regulatory environment, and market volatility.

Management Comments

• "We continue to execute against our strategy by advancing our next-generation in vivo CAR-T platform, expanding our expertise with the appointment of two new board members and strengthening our development capabilities through a new collaboration focused on our next-generation in vivo CAR-T candidate, TPST-4003," said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest.
• "These milestones reflect the momentum we are building across the business and reinforce our commitment to developing innovative therapies aiming to transform patient care."
• "We are particularly excited to advance TPST-4003 toward an investigator-initiated clinical trial planned for the fourth quarter of 2026, an important step as we work to bring transformative options to patients."

Industry Context

StockSavvy.ai notes that Tempest Therapeutics is operating in the highly competitive and rapidly evolving CAR-T therapy space. The focus on in vivo CAR-T and next-generation delivery platforms, such as mRNA/LNP, reflects industry trends aiming for improved safety, efficacy, and accessibility compared to traditional ex vivo CAR-T therapies. The collaboration with Senlang Biotechnology and the partnership with Novatim Immune Therapeutics are strategic moves to leverage external expertise and resources, common in biotech to de-risk development and accelerate progress.

Management Changes

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises, but also potential upside from successful clinical development and partnerships.
• Employees: Continued focus on R&D and business development may create opportunities, but the company's financial position and need for capital present ongoing uncertainty.
• Partners/Suppliers: The collaboration with Senlang Biotechnology and the engagement of Cincinnati Childrens AGCTC indicate ongoing and new business relationships.
• Creditors: The company's negative equity and cash position suggest potential reliance on debt or equity financing, impacting creditors.

Next Steps

• Advance TPST-4003 towards an investigator-initiated clinical trial planned for Q4 2026.
• Obtain initial clinical data for TPST-4003 in H1 2027.
• Initiate the first potentially registrational study for TPST-2003 later in 2026.
• Continue business development efforts, including expanding outreach and partnering in China.

Key Dates

Recommendation

The company shows promising clinical development with positive early data and strategic partnerships, which are significant positives. However, the substantial decrease in cash reserves and the ongoing need for capital represent a material risk. The current stage of development and financial situation warrant a 'hold' recommendation, pending further clarity on financing and clinical trial progression.

Keywords

CAR-T, in vivo CAR-T, TPST-4003, TPST-2003, biotechnology, oncology, autoimmune, clinical-stage